AstraZeneca Results Presentation Deck

Percentage mean change in UACR from baseline to week 12 BioPharmaceuticals - R&D highlights Data at ASN and ERS publication support Phase III trials 0% -10% -20% -30% -40% -50% -60% zibotentan / dapagliflozin Chronic Kidney Disease with high proteinuria Phase II ZENITH: UACR reduction UACR >30mg/g signals presence of urine albumin, marker for CKD zibo/dapa (1.5/10mg) zibo/dapa (0.25/10mg) CEO Opening Remarks -53% -48% zibo/dapa demonstrated clinically meaningful reduction in UACR across both doses dapa (10mg) -28% SOCIETY Phase III trial initiated, opportunity to increase patient benefit with synergistic combination treatment OF LOGI Financial Results ១០ Oncology RAGE/EGFR pathway (IL-33⁰x) preventing epithelial dysfunction COPD Severe viral LRTD Asthma, COPD tozorakimab | IL-33 mAb BioPharmaceuticals EGFR Y OBERON, TITANIA, MIRANDA Rare Disease TILIA FRONTIER-3, FRONTIER-4 (Phase II) CEO Closing Remarks ST2 pathway (IL-33red) preventing airway inflammation >2024 >2024 UPCOMING 1. Based on KDIGO guidelines; high proteinuria defined as UACR >300m/g. 2. Global Burden of Disease Study 2019, Lower Respiratory Infection collaborators 3. ACCORD-2 is a University of Southampton trial that investigated potential treatments for patients hospitalised with COVID-19 during the pandemic 4. Odds ratio adjusted for age and baseline COVID-19 severity. 5. IL-33/SST2 complex biomarker defined as patients with 230.15U/mL. 25 ASN = American Society of Nephrology; ERS = European Respiratory Society; CKD = chronic kidney disease; UACR = urine albumin-to-creatinine ratio; zibo = zibotentan; dapa = dapagliflozin (Farxiga); SoC = standard-of-care; IL-33 = interleukin-33; SST2 = soluble suppression of tumorigenesis-2; LRTD = lower respiratory tract disease. Dual pathway inhibition could provide a unique opportunity in inflammatory diseases

View entire presentation